Home・Elenco Azioni・Beam Therapeutics Inc

Beam Therapeutics Inc

Chiusa

SettoreSettore sanitario

26.72 1.17

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.7

Massimo

26.86

Metriche Chiave
By Trading Economics
Entrata	-28M -123M
Vendite	-31M 490K
EPS	-1.18
Margine di Profitto	-25,036.327
Dipendenti	540
EBITDA	-36M -125M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+97.28% upside

Dividendi
By Acuity
Utili prossimi	2 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	152M 2.8B
Apertura precedente	25.55
Chiusura precedente	26.72

Notizie sul Sentiment di mercato

By Acuity

50%

163 / 340 Classifica in Healthcare

Beam Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 ago 2026, 19:36 UTC

Beam Therapeutics is trading higher during Friday's session, recovering from an earlier dip. No specific news has been identified to explain the price action.

13 ago 2026, 23:01 UTC

Beam Therapeutics Inc. shares are higher in after-market trading, reflecting notable upward momentum since Thursday's close, despite no specific news identified.

12 ago 2026, 20:06 UTC

Beam Therapeutics Inc. shares are lower today, continuing a trend of declines since Tuesday's close amid broader market uncertainties and lower U.S. Treasury yields.

11 ago 2026, 23:06 UTC

Beam Therapeutics shares are higher in after-market trading, following a session peak. No specific news was identified to explain the price movement.

5 ago 2026, 19:52 UTC

Correlated Moves

Beam Therapeutics Inc is trading lower as broader market sentiment weakens. The decline follows disappointing ADP employment data, which missed expectations significantly.

4 ago 2026, 23:06 UTC

Beam Therapeutics Inc. shares are lower in after-market hours, following a session low shortly after the open, despite three consecutive higher daily closes.

3 ago 2026, 19:16 UTC

Correlated Moves

News

Beam Therapeutics is rising amid a broader market rally, with a market cap of $2.64 billion and $1.2 billion in liquidity to support operations.

31 lug 2026, 19:16 UTC

Correlated Moves

Beam Therapeutics shares are lower, reflecting a decline in first-quarter results and broader sector weakness. The stock remains near the lower end of its one-month range.

30 lug 2026, 23:06 UTC

Beam Therapeutics Inc shares are higher in after-hours trading, advancing since Thursday's close, despite remaining below the 20-day moving average.

29 lug 2026, 22:51 UTC

Beam Therapeutics shares are lower in after-market hours following a volatile session, amid broader market uncertainty after the Federal Reserve's interest rate decision.

28 lug 2026, 23:51 UTC

Beam Therapeutics Inc shares are lower in after-market trading, experiencing unusual volatility amid broader market declines and positioned below its 20-day moving average.

27 lug 2026, 23:06 UTC

Beam Therapeutics Inc shares are higher in after-market hours, despite a broader decline in trading. No specific news was identified to explain the increase.

24 lug 2026, 19:26 UTC

Event

Correlated Moves

Beam Therapeutics is declining today, reflecting broader market trends, with the Russell 2000 Index down. The stock remains below its 20-day moving average.

23 lug 2026, 09:51 UTC

News

Beam Therapeutics is higher in pre-market trading, driven by significant upcoming clinical milestones, including the global BEAM-302 trial and an FDA application for risto-cel.

22 lug 2026, 23:46 UTC

Beam Therapeutics shares higher in after-market trading, advancing since Wednesday's close. The stock remains below its 20-day moving average amid broader market influences.

21 lug 2026, 18:06 UTC

Correlated Moves

Beam Therapeutics shares are higher today, reflecting positive sentiment in small-cap stocks amid anticipation of upcoming earnings results from major companies.

20 lug 2026, 23:56 UTC

Beam Therapeutics Inc is higher in after-market trading, showing notable strength since Monday's close. No specific news was identified to explain the movement.

Confronto tra pari

Modifica del prezzo

Beam Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

97.28% in crescita

Previsioni per 12 mesi

Media 52.3 USD 97.28%

Alto 80 USD

Basso 26 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Beam Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Beam Therapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

163 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.